ZTSZTSHealthcare · Drug Manufacturers - Specialty & Generic

ZTS Stock Forecast: Zoetis, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$86
+2.50% on the day

The 16 Wall Street analysts covering Zoetis, Inc. hold a median 12-month price target of $85 — -0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$33.9B
Ticker Nerd rank
64/ 100
Median analyst target
$85
Analysts covering
16
Revenue$2.5B+0.3% y/y
Operating income$999.0M
Net income$691.0M
Free cash flow$538.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.6%
1M
+8.5%
YTD
−30.5%
1Y
−25.9%
From 52W high
−33.5%
From 52W low
+24.7%
$69
$129
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zoetis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
64/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
99
Quality
95
Revisions
62
Issuance
53
Growth
47
Accruals
45
Momentum
24
Size
7

Volatility (99): The share price has been relatively steady.

Momentum (24): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ZTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110$120$130Jan 26Apr 26Jul 26Oct 26ZTSHigh $115Median $85Low $73

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
6 Buy10 Hold0 Sell
Low $73Median $85High $115

The green dot is the last close — the median target sits −0.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 9 moved it down.

DateFirmActionRatingTarget
29 Oct 2026Morgan StanleyMaintainsOverweight$85 → $82
27 Oct 2026UBSMaintainsNeutral$80 → $85
20 Oct 2026JefferiesDowngradeHold—
20 Oct 2026JefferiesDowngradeHold$103 → $83
16 Oct 2026Goldman SachsInitiatesNeutral—
16 Oct 2026Goldman SachsInitiatesNeutral$74
25 Aug 2026TD CowenMaintainsBuy$104 → $94
25 Aug 2026TD CowenMaintainsBuy—
20 Aug 2026StifelMaintainsHold$85 → $80
20 Aug 2026StifelMaintainsHold—
11 Aug 2026BNP ParibasMaintainsOutperform—
11 Aug 2026BNP ParibasMaintainsOutperform$146 → $110
11 Aug 2026CitigroupMaintainsBuy$112 → $96
11 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026Piper SandlerMaintainsNeutral$90 → $80
10 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026JP MorganMaintainsOverweight$130 → $115
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026UBSMaintainsNeutral$85 → $80
7 Aug 2026UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ZTS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ZTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Zoetis, Inc. returned −25.9% against +12.2% for the S&P 500, dividends included.

ZTS vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26ZTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.1%
Analysts raising
7
Analysts cutting
0
Fundamentals

Zoetis, Inc. (ZTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.3×

Cheaper than 46% of US stocks

Price / sales
3.6×

Cheaper than 32% of US stocks

Price / book
10.3×

Cheaper than 8% of US stocks

EV / EBITDA
10.3×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
−1.3%

Higher than 26% of US stocks

Earnings growth (YoY)
−18.0%

Higher than 22% of US stocks

Gross margin
72.7%

Higher than 85% of US stocks

Operating margin
37.9%

Higher than 92% of US stocks

Net margin
26.4%

Higher than 86% of US stocks

Returns & dividend
Return on equity
57.6%

Higher than 94% of US stocks

Return on assets
14.9%

Higher than 97% of US stocks

Dividend yield
2.5%

Higher than 83% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zoetis, Inc. (ZTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zoetis, Inc. has a market value of $33.9B and an enterprise value of $41.6B.

  • Revenue in the twelve months to 30 June 2026: $9.5B. The latest quarter shrank 1.3% year on year.

  • Net income over the same four quarters: $2.6B, a 27.5% net margin.

  • Diluted earnings per share, trailing twelve months: $6.07.

  • Free cash flow in the twelve months to 30 June 2026: $2.3B, after $524.0M of capital spending.

  • Zoetis, Inc. spent $3.6B on share buybacks and $889.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 414.2M.

  • Trailing P/E: 14.3×; forward P/E: 13.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.54%, paying out 35% of earnings.

  • Zoetis, Inc. employs 14,500 people — $656K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ZTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ZTSZoetis, Inc.$33.9B64
UTHRUnited Therapeutics Corp.$24.8B79
VTRSViatris, Inc.$23.6B100
NBIXNeurocrine Biosciences, Inc.$16.5B96
ELANElanco Animal Health, Inc.$12.9B97
ALKSAlkermes Plc$7.5B70
AMRXAmneal Pharmaceuticals, Inc.$7.4B83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zoetis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZTS news & analysis

Top 50 High-Quality Dividend Growth Stocks For November 2026

Seeking Alpha · 14 Nov 2026neutral

The article tracks 50 high-quality dividend growth stocks, assessing entry points, estimated total returns, and valuation relative to historical free cash flow. It reports that 40 stocks have estimated future returns of at least 10% and 27 appear undervalued; ResMed and MarketAxess are highlighted.

Why it matters — The excerpt provides broad dividend-growth and valuation context but does not mention Zoetis, so it offers no company-specific update for ZTS watchers.

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

Zacks Investment Research · 12 Nov 2026positive

Zoetis’ Cytopoint Plus received a USDA license for use in dogs with allergic dermatitis, providing 75 days of itch relief and a longer interval between injections.

Why it matters — The license adds a longer-duration treatment option to Zoetis’ portfolio for canine allergic dermatitis.

SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026

Seeking Alpha · 12 Nov 2026neutral

A Seeking Alpha article outlines a four-factor dividend-growth strategy using free cash flow to debt, five-year dividend growth, return on capital employed, and forward yield. It reports an average return of 14.98% versus SCHD’s 14.31%, while noting that recent SCHD outperformance narrowed the gap and the strategy regained momentum since September 2026.

Why it matters — The item describes a dividend-growth strategy and its performance but provides no specific information about Zoetis, so its relevance to ZTS is limited.

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

Business Wire · 11 Nov 2026positive

Zoetis received a USDA license for Cytopoint Plus, described as a next-generation monoclonal antibody that provides 75 days of allergic itch relief in dogs with allergic dermatitis from a single injection.

Why it matters — The license adds a new long-acting canine allergy treatment to Zoetis's animal-health portfolio.

FAQ

Frequently asked questions about ZTS stock

What is the ZTS stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Zoetis, Inc. have a median 12-month price target of $85, with estimates ranging from $73 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZTS stock a buy right now?

Of the 16 analysts covering Zoetis, Inc., 6 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zoetis, Inc. 64 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZTS?

As at 17 Nov 2026, Zoetis, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will ZTS stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies -0.7% from the last close, and Ticker Nerd's factor model ranks Zoetis, Inc. 64 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZTS stock forecast for 2030?

No analyst covering Zoetis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $73 to $115 over the next 12 months.

How has ZTS stock performed over the past year?

Zoetis, Inc. returned -25.9% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zoetis, Inc. do?

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock.

What is the latest news on ZTS?

The most recent item we track (Seeking Alpha, 16 Nov 2026): "Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript". Zoetis Inc. presented at the Jefferies Global Healthcare Conference 2026; the source provides a transcript of the presentation.

Company

About Zoetis, Inc.

Zoetis Inc. Class A Common Stock represents Zoetis, a global animal health company focused on medicines, vaccines, diagnostics, and related technologies for pets and livestock. Zoetis develops and markets products used by veterinarians, livestock producers, and pet owners across companion animals such as dogs, cats, and horses, as well as livestock including cattle, swine, poultry, fish, and sheep. Its portfolio includes parasiticides, dermatology treatments, pain and sedation products, anti-infectives, diagnostic tools, genetic tests, and precision animal health solutions. The company also provides reference laboratory services, rapid tests, instruments, and other non-pharmaceutical offerings that support disease detection and animal care. Headquartered in Parsippany, New Jersey, Zoetis operates in the United States and international markets, serving a broad range of animal health needs across clinical, agricultural, and diagnostic settings.

CEO Ms. Kristin C. Peck · 14,500 employees · United States · https://www.zoetis.com